Messenger Rna

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

Adjuvant treatment with messenger RNA in combination with Keytruda produced meaningful improvement in patients with resected high-risk melanoma, according to findings from a phase 2b study.

The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó, PhD, and Drew Weissman, MD, PhD, for discoveries that were crucial in developing messenger RNA vaccines to combat the spread of COVID-19, according to a press release.

Moderna has initiated the rolling submission process for its respiratory syncytial virus vaccine candidate mRNA-1345, the company announced Wednesday.

Bivalent messenger RNA booster vaccinations were effective for preventing COVID-19 hospitalizations and deaths in older adults, according to data presented at the European Congress of Clinical Microbiology & Infectious Diseases.

SEATTLE — In January, Janssen discontinued the phase 3 MOSAICO trial because the HIV vaccine regimen it was testing did not prevent infection — the latest in a string of failed HIV vaccine trials.

CDC researchers found that vaccination with a bivalent messenger RNA booster was effective against the XBB.1.5 subvariant of SARS-CoV-2.

Moderna announced Tuesday that its RNA-based respiratory syncytial virus vaccine has met primary endpoints in a phase 3 trial showing that the vaccine is both safe and highly effective in older adults.

Researchers identified the presence of circulating spike protein that evaded antibody recognition in adolescents and young adults who present with myocarditis after SARS-CoV-2 messenger RNA vaccination.

A database analysis showed no association between messenger RNA COVID-19 vaccines and risk for acute MI, stroke or pulmonary embolism, but a slight increase in risk for PE and MI after receiving the AstraZeneca or Janssen vaccines.